4:15
Advanced Hodgkin lymphoma: AHL2011 data update from EHA 2018
Olivier Casasnovas
1:57
Biomarkers in lymphoma
Arjan Diepstra
3:31
Brentuximab vedotin plus ESHAP: complete remission in R/R Hodgkin lymphoma
Ramon Garcia-Sanz
2:22
Novel therapies in minimizing transplant complications
Mohamad Mohty
3:00
EBMT 2018: Updates on advanced Hodgkin lymphoma treatment
Martin Hutchings
1:31
ABVD vs. escBEACOPP in HL: a 10-year study
George Follows
1:13
Checkpoint inhibitor/bispecific antibody combo: REGN2810 and REGN1979 in B-lymphoid malignancies
Anthony Mato
3:09
ECHELON-1 trial data from ASH 2017: controversies and clinical translation
Graham Collins
2:30
New antibody-drug conjugates for lymphoma
Graham Collins
iwNHL 2017: T-cell lymphomas, Hodgkin’s lymphoma, immunotherapy and epigenetics
Francesco d'Amore et al.
1:47
Latest research in Hodgkin lymphoma
Anas Younes
5:37
Key abstracts being presented at ASH 2017
Anas Younes
1:15
The future for the treatment of Hodgkin lymphoma
Stephen Ansell
1:30
Next-generation sequencing in patients with lymphoid malignancies
Ola Landgren
1:28
CAR-T cell therapy debate: the future of lymphoma treatment?
Graham Collins
2:30
New lymphoma drug studies show promise
Graham Collins
VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

The content of VJHemOnc is intended for healthcare professionals